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Impact of Diabetes Mellitus on Angiographic Outcomes in Patients with Different
Drug-eluting Stents
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Background: There is currently no data to evaluate the differences of drug-eluting
stents on the angiographic outcomes of diabetes mellitus (DM) patients. To evaluate
the effects of different drug-eluting stents on the outcomes of DM patients, we
investigated serial angiographic outcomes after drug-eluting stent placement.
Methods: From 2002 to 2012, 10983 consecutive de-novo coronary lesions were
treated using drug-eluting stents (biolimus-eluting stent (BES); n¼1367, everolimus-
eluting stent (EES); n¼2983, paclitaxel-eluting stent (PES); n¼1215, sirolimus-
eluting stent (SES); n¼5418). 41% were DM and 10% were insulin-treated patients.
Angiographic follow-up was routinely performed 8 months after a successful proce-
dure (follow-up rate was 82%). Angiographic outcomes were compared among pa-
tients with the implanted stent types.
Results: The binary restenosis rates were 6.6% in non-DM patients, 11.0% in non-
insulin-requiring DM patients, and 14.0% in insulin-treated DM patients. The SES,
PES and BES groups had higher restenosis rates in non-insulin-requiring DM patients
compared with non-DM patients (SES; 6.1% vs. 10.4%, p< 0.001, PES; 12.0% vs.
21.7%, p< 0.001, BES 5.9% vs. 9.1%, p¼0.04). Binary restenosis in the EES group
were similar between non-DM patients and non-insulin-requiring DM patients (5.5%
vs. 5.6%, p¼0.92). A multivariable analysis showed that DM was an independent
predictor of recurrent restenosis in implantation of SES (odds ratio [OR]: 1.98, 95%
conﬁdence interval [CI]: 1.59 to 2.46, p< 0.001), PES (OR: 1.74, CI: 1.22 to 2.48,
p¼0.002), and BES (OR: 1.60, CI: 1.01 to 2.53, p¼0.04), except EES (OR: 1.19, CI:
0.85 to 1.67, p¼0.30).
Conclusions: Percutaneous coronary intervention in DM patients is associated with
worse angiographic outcomes compared with those in non-DM patients. The use of
EES could be effective for DM patients.
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Background: To evaluate whether the impact on clinical outcomes of newer vs. ﬁrst
generation drug-eluting stents (DES) is inﬂuenced by diabetes mellitus (DM).
Methods: We pooled patient-level data of 10,448 women undergoing PCI with DES
from 26 randomized trials. Baseline characteristics and long-term clinical outcomes
were stratiﬁed according to baseline DM status and DES type (new vs. ﬁrst genera-
tion). Associations between stent type and outcomes were examined within each
stratum using Cox regression with trial entered as a random effect. The primary
endpoint was the composite of all-cause death and myocardial infarction (MI). Sec-
ondary endpoints were target-lesion revascularization (TLR) and deﬁnite or probable
stent thrombosis (ST).
Results: DM was present in 3,294 (31.5%) of women treated with DES. In women
without DM, use of new generation compared with ﬁrst generation DES was asso-
ciated with reduced risks of death or MI (7.6% vs. 10.2%; adjHR 0.69, 95%CI, 95%CI
0.55-0.88), ST (0.8% vs. 1.7%; adjHR 0.32, 95%CI 0.17-0.62) and TLR (5.3% vs.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Li6.9%; adjHR 0.74, 95%CI 0.56-0.99). No major differences were observed between
new and ﬁrst generation DES for death or MI (12.8% vs. 12.4%; adjHR 0.90, 95%CI,
95%CI 0.69-1.19), ST (2.0% vs. 3.1%; adjHR 0.84, 95%CI 0.47-1.49) and TLR
(8.7% vs. 9.5%; adjHR 1.14, 95%CI 0.82-1.59) among women with DM (Figure).




Conclusions: The safety and efﬁcacy proﬁle of new generation compared with ﬁrst
generation DES among women varies according to the presence of DM with enhanced
beneﬁts in women without DM.
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Background: It is still unknown whether different stent types of new-generation
cobalt-chromium drug-eluting stent (DES) correlate with clinical outcomes in patients
with diabetes.
Methods: Across 2 Italian centers, we retrospectively evaluated the primary endpoint
of major adverse cardiac events (MACE) amongst patients receiving new-generation
zotarolimus-eluting stents (ZES: Resolute family [Medtronic, Santa Rosa, CA]) and
everolimus-eluting stents (EES: Xience family [Abbott Vascular, Santa Clara, CA]
and PROMUS stent [Boston Scientiﬁc, Natick, MA]). Secondary endpoints included
the composite endpoint of all-cause mortality and any myocardial infarction (MI), and
any target lesion revascularization (TLR).
Results: Four hundred patients with 553 coronary lesions treated with ZES (136
patients, 196 lesions) and EES (264 patients, 357 lesions) between October 2006 and
August 2012 were included in the present study. Patient demographics and other
cardiovascular risk factors were similar between the two groups. Multi-vessel PCI
(23.5% vs. 14.0%, p¼0.017), a PCI for restenotic lesion (26.0% vs. 15.4%, p¼0.002),
IVUS usage (30.1% vs. 17.4%, p¼0.001) were signiﬁcantly higher in the ZES group,
whereas implantation of smaller vessel stents (2.5mm) was statistically higher in the
EES group (27.6% vs. 37.8%, p¼0.015). At the follow-up period of 720 days, there
was no signiﬁcant difference in MACE between ZES and EES (22.8% vs. 18.1%,
HR¼1.11, 95%CI: 0.67-1.85). Similarly no signiﬁcant differences were observed in
the composite endpoint of death or MI (9.1% vs. 10.3%, HR¼1.14, 95%CI: 0.54-
2.40) or TLR (12.4% vs. 6.9%, HR¼1.53, 95%CI; 0.81-2.89).
Conclusions: The present study showed that no signiﬁcant differences in each outcomes
(MACE, all-cause mortality/MI, TLR) were observed in diabetic patients treated with
new-generation cobalt-chromium ZES and EES. Even though, our study cohort
constituted of more complex lesions and patient characteristics, our ﬁndings resemble
the ones reported in previous randomized control studies in the general population.Lipid Disorders and Management
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Background: Reducing the expression of endothelial cell adhesion molecules
(ECAMs) is conducive to the decrease of inﬂammation-induced vascular complica-
tions. In this study, we observed Pitavastatin on the expression of vascular cell
adhesion molecule-1 (VCAM-1) and its inﬂuence on VCAM-1’s target gene miR-126
in cultured human umbilical vein endothelial cells (HUVEC) activated by tumor
ncrosis factor-a (TNF-a). The purpose of this study is to explore the mechanism of
pitavastatin in prevention and treatment of atherosclerosis (AS).
Methods: HUVEC were cultured in M1640 supplemented with 10% bovine calf serum
and passages 2 to 5were used in experiments. The cells were randomly divided into threepid Disorders and Management B73
